Minimal residual disease in melanoma.

Evaluation of Relationship between Minimal Residual Disease (MRD) and Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) Using Quantitative Fluorescent PCR

The relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia

Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...

On the cusp of a revolution: melanoma molecular diagnostics.

‘‘New markers exist that correlate with melanoma progression, which may aid in melanoma identification, prognostication, and detection of minimal residual disease/early recurrence.’’ ‘‘We now understand that it is not sufficient to identify a tumor based on histology or the organ or origin as we have done traditionally but rather we now need to understand the particular molecular driver of the ...

Trick and treat

Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.

Pigmented Bowens disease mimicking malignant Melanoma: A case report

Pigmented Bowens disease is an in situ squamous cell carcinoma, which is seldom reported in white patients. Herein we report a 20-year-old woman with type III skin, who had this lesion on the fourth finger of her right hand, similar to superficial malignant melanoma, clinically. Although dermoscopic evaluation could be helpful, correct diagnosis of non-melanotic origin is done by histological e...